A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial

Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) is the standard of care for untreated diffuse large B-cell lymphoma (DLBCL). However, the schedule for rituximab administration has not been optimized. To compare standard R-CHOP with CHOP plus dose-dense weekly rituximab (R...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Ohmachi, Ken, Kinoshita, Tomohiro, Tobinai, Kensei, Ogawa, Gakuto, Mizutani, Tomonori, Yamauchi, Nobuhiko, Fukuhara, Noriko, Uchida, Toshiki, Yamamoto, Kazuhito, Miyazaki, Kana, Tsukamoto, Norifumi, Iida, Shinsuke, Utsumi, Takahiko, Yoshida, Isao, Imaizumi, Yoshitaka, Tokunaga, Takashi, Yoshida, Shinichiro, Masaki, Yasufumi, Murayama, Tohru, Yakushijin, Yoshihiro, Suehiro, Youko, Nosaka, Kisato, Dobashi, Nobuaki, Kuroda, Junya, Takamatsu, Yasushi, Maruyama, Dai, Ando, Kiyoshi, Ishizawa, Kenichi, Ogura, Michinori, Yoshino, Tadashi, Hotta, Tomomitsu, Tsukasaki, Kunihiro, Nagai, Hirokazu
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7903239/
https://ncbi.nlm.nih.gov/pubmed/33591324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002567
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados